PAYS — what changed in the latest 10-Q
A section-by-section comparison of PAYS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-06 vs the prior 10-Q · 2026-05-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +17 | −4 | ~22 | 18 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-06
Comparison of the Six Months Ended June 30, 2026 to the Six Months Ended June 30, 2025
The following table summarizes our condensed consolidated financial results for the six months ended June 30, 2026 in comparison to the six months ended June 30, 2025:
The increase in total revenues of $18,613,993 for the six months ended June 30, 2026 compared to the same period in the prior year consisted primarily of a $4,635,347 increase in plasma revenue, a $13,956,026 increase in pharma revenue and a $22,620 increase in other revenue. The increase in plasma …
Cost of revenues for the six months ended June 30, 2026 increased $5,944,018 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, call cente…
Gross profit for the six months ended June 30, 2026 increased $12,669,975 compared to the same period in the prior year resulting primarily from the launch of an additional 51 net pharma patient affordability programs during the prior twelve-month period, and a corresponding increase in setup fees, …
Text removed vs the prior filing · source: 10-Q · 2026-05-13
Management reviews a number of metrics to help us monitor the performance of and identify trends affecting our business. We believe the following measures are the primary indicators of our quarterly and annual revenues:
Gross Dollar Volume Loaded on Cards: Represents the total dollar volume of funds loaded to all our prepaid card programs. Our gross dollar volume loaded on cards was $514 million and $407 million for the three months ended March 31, 2026 and 2025, respectively. We use this metric to analyze the tota…
Conversion Rates on Gross Dollar Volume Loaded on Cards: Represents revenues, gross profit or net income conversion rates of gross dollar volume loaded on cards which are calculated by taking our total revenues, gross profit or net income, respectively, as a numerator and dividing by the gross dolla…
We used net cash in investing activities during the three months ended March 31, 2026 and 2025 of $2,075,341 and $4,443,855, respectively. For the three months ended March 31, 2026, cash was used for investing activities primarily attributable to an increase in licenses, fixed assets and capitalizat…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice